Citius Oncology Shares Skyrocket 35% in Pre-Market Following Major Distribution Deal
Citius Oncology Shares Jump 35% in Pre-market After New Drug Deal. Citius Oncology made headlines this week. Its stock soared more than 35% in Pre-market in one day. Why? The company signed a major distribution deal for its new cancer drug, LYMPHIR™. This drug is designed to treat cutaneous T-cell lymphoma, a rare type of…